Abstract
Acute gastroenteritis is associated with significant morbidity in developed countries and each year is the cause of death of several million children in developing countries. Acute gastroenteritis is usually self-limiting. Oral rehydration therapy (ORT) is effective and successful in the majority of patients. Vomiting is common at the outset of viral gastroenteritis and can limit the effectiveness of ORT. Treatment with newer anti-emetic medications has been reported to facilitate ORT and to minimize the risk of dehydration and the need for intravenous hydration and hospitalization.
The role of anti-emetic medications in the treatment of gastroenteritis-related vomiting is not clear. Some physicians agree with the use of anti-emetic medications because vomiting is unpleasant and distressing for the child and parents alike, and because vomiting can increase the likelihood of dehydration, electrolyte imbalance, and the need for intravenous hydration or hospitalization. Several surveys have shown that anti-emetic medications are commonly prescribed in the treatment of pediatric gastroenteritis and that adverse events are uncommon. Efficacy studies of the newer anti-emetic medications are now available and reveal that some are effective and help facilitate ORT. Other physicians disagree with the use of anti-emetic medications because acute gastroenteritis is a self-limiting condition, vomiting might help rid the body of toxic substances, there was previously a relative lack of published evidence of clinical benefit, and there are potential adverse events associated with the use of an anti-emetic medication.
Anti-emetic medications that are currently available include ondansetron, granisetron, tropisetron, dolasetron, ramosetron, promethazine, dimenhydrinate, metoclopramide, domperidone, droperidol, prochlorperazine, and trimethobenzamide. Randomized, placebo-controlled trials suggest that ondansetron is efficacious and superior to other anti-emetic medications in the treatment of gastroenteritis-related vomiting. A recent double-blind clinical trial showed that a single oral dose of ondansetron reduces gastroenteritis-related vomiting and facilitates ORT without significant adverse events. Ondansetron shows promise as a first-line anti-emetic, and judicious use of this agent might increase the success of ORT, minimize the need for intravenous therapy and hospitalization, and reduce healthcare costs. Ondansetron should be considered in situations where vomiting hinders ORT, but a larger randomized, placebo-controlled trial is necessary before the medication can be routinely recommended for the treatment of gastroenteritis-related vomiting in children.
Similar content being viewed by others
References
Cubbedu LX, Trujllo LM, Talmaciu I, et al. Anti-emetic activity of odansetron in acute gastroenteritis. Aliment Pharmacol Ther 1997; 11: 185–91
American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Practice parameter: the management of acute gastroenteritis in young children. Pediatrics 1996; 97: 424–35
Freedman SB, Adler M, Seshadri R, et al. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 2006; 354: 1698–705
Ramsook C, Sahagun-Curreon I, Kuzinetz CA, et al. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med 2002; 39: 397–403
Reeves JJ, Shannon MW, Fleisher GR. Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized controlled trial. Pediatrics 2002; 109(4): e62
van Eygen M, Heck E, Dhondt F, et al. A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. Postgrad Med J 1979; 55Suppl. 1: 36–9
Dalby-Payne J, Elliott E. Gastroenteritis in children. Clin Evid 2004; 12: 443–54
Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005; 22: 476–87
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv Ther 2006; 23: 519–27
Murray KF, Christie DL. Vomiting. Pediatr Rev 1998; 19: 337–41
Burkhart D. Management of acute gastroenteritis in children. Am Fam Physician 1999; 60: 2555–63
Northrup RS, Flanigan TP. Gastroenteritis. Pediatr Rev 1994; 15: 461–71
Glass R, Lew J, Gangarosa R, et al. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr 1991; 118: S27–33
Ho MS, Glass RI, Pinsky PF, et al. Diarrheal deaths in American children: are they preventable? JAMA 1988; 260: 3281–5
Kwon KT, Rudkin SE, Langdorf MI. Anti-emetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians. Clin Pediatr 2002; 41: 641–52
King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52(RR16): 1–16
Santosham M. Oral rehydration therapy: reverse transfer of technology. Arch Pediatr Adolesc Med 2002; 156: 1177–9
Jafri S, Pasricha PJ. Antinausea and anti-emetic medications. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman’s the pharmacological basics of therapeutics. New York: McGraw-Hill, 2001: 1029–33
Keller VE. Management of nausea and vomiting in children. J Pediatr Nurs 1995; 10: 280–6
Freedman SB, Fuchs S. Anti-emetic therapy in pediatric emergency departments. Pediatr Emerg Care 2004; 20: 625–32
Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173–89
Olutoye O, Watcha MF. Management of postoperative vomiting in pediatric patients. Int Anesth Clin 2003; 41: 99–117
Flake ZA, Scalley RD, Bailey AG. Practical selection of anti-emetic medication. Am Fam Physician 2004; 69: 1169–74
Acker ME. Vomiting in children: a comprehensive review. Adv Nurse Pract 2002; 31: 51–68
Duggan C, Lasche J, McCarty M, et al. Oral rehydration solution for acute diarrhea prevents subsequent unscheduled follow-up visits. Pediatrics 1999; 104(3): e29
Leung AK, Darling P, Auclair C. Oral rehydration therapy: a review. J R Soc Health 1987; 107: 64–7
Issenman RM, Leung AK. Oral and intravenous rehydration of children. Can Fam Physician 1993; 39: 2129–36
Nutrition and Gastroenterology Committee, Canadian Paediatric Society. Oral rehydration therapy and early refeeding in the management of childhood gastroenteritis. Paediatr Child Health 2006; 11: 527–31
Report of an ESPGAN Working Group. Recommendations for composition of oral rehydration solutions for children of Europe. J Pediatr Gastroenterol Nutr 1992; 14: 113–5
Leung AK, Taylor PG, Geoffroy L, et al. Efficacy and safety of two oral solutions as maintenance therapy for acute diarrhea: a double-blind, randomized, multi-center trial. Clin Pediatr (Phila) 1988; 31: 631–5
Santosham M, Burns B, Nadkami V, et al. Oral rehydration therapy for acute diarrhea in ambulatory children in the United States: a double-blind comparison of four different solutions. Pediatrics 1985; 76: 159–66
Tamer AM, Friedman LB, Maxwell SR, et al. Oral rehydration of infants in a large urban US medical center. J Pediatr 1985; 107: 14–9
Leung AK, Robson WL. Acute diarrhea in children: what to do and what not to do. Postgrad Med 1989; 86(8): 161–74
Sentongo TA. The use of oral rehydration solutions in children and adults. Curr Gastroenterol Rep 2004; 6: 307–13
Ernst AA, Weiss SJ, Park S, et al. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double-blind clinical trial. Ann Emerg Med 2000; 36: 89–94
Li STT, DiGiuseppe DL, Christakis DA. Anti-emetic use for acute gastroenteritis in children. Arch Pediatr Adolesc Med 2003; 157: 475–9
Elliott EJ, Backhouse JA, Leach JW. Pre-admission management of acute gastroenteritis. J Paediatr Child Health 1996; 32: 18–21
O’Loughlin EV, Notaras E, McCullough C, et al. Home-based management of children hospitalized with acute gastroenteritis. J Paediatr Child Health 1995; 31: 189–91
Webb A, Starr M. Acute gastroenteritis in children. Aust Fam Physician 2005; 34: 227–31
Christakis DA, Wright JA, Rivara F. Promethazine therapy for gastroenteritis: towards a better understanding of use, risks and benefits. Ambul Child Health 1998; 4: 181–7
Albano F, Bruzzese E, Spagnuolo M, et al. Antiemetics for children with gastroenteritis: off label but still on in clinical practice. J Pediatr Gastroenterol Nutr 2006; 43: 402–4
Alhashimi D, Alhashimi H, Fedorowicz Z. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev 2006 Oct 18; (4): CD005506
Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995; 29: 95–109
Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an anti-emetic in children. Pediatr Drugs 2001; 3: 441–79
Scuderi PE. Pharmacology of anti-emetic medication. Int Anesth Clin 2003; 41: 41–66
Carden PA, Mitchell SL, Waters KD, et al. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. J Clin Oncol 1990; 8: 1531–5
Cohen IJ, Zehavi N, Buchwald I, et al. Oral ondansetron: an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol Oncol 1995; 12: 67–72
Hewitt M, McQuade B, Stevens R. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. Clin Oncol R Coll Radiol 1993; 5: 11–4
Holdsworth MT, Raisch DW, Duncan MH, et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 1995; 29: 16–21
Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology 1992; 49: 279–85
Kolecki P, Wachowiak J, Beshari SE. Ondansetron as an effective drug in prophylaxis of chemotherapy-induced emesis in children. Acta Hematol Pol 1993; 24: 115–22
Lippens RJ, Broeders GC. Ondansetron in radiation therapy of brain tumor in children. Pediatr Hematol Oncol 1996; 13: 247–52
Pinkerton CR, Williams D, Wootton C, et al. 5-HT3 antagonist ondansetron: an effective outpatient anti-emetic in cancer treatment. Arch Dis Child 1990; 65: 822–5
Sullivan MJ, Abbott GD, Robinson BA. Ondansetron anti-emetic therapy for chemotherapy and radiotherapy induced vomiting in children. NZ Med J 1992; 105: 369–71
Domino KB, Anderson EA, Polissar NL, et al. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999; 88: 1370–9
Morton NS, Camu F, Dorman T, et al. Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy. Paediatr Anaesth 1997; 7: 37–45
Polati E, Verlato G, Finco G, et al. Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. Anesth Analg 1997; 85: 395–9
Splinter WM, Rhine EJ, Roberts DW, et al. Ondansetron is a better prophylactic anti-emetic than droperidol for tonsillectomy in children. J Anaesth 1995; 42: 848–51
Stene EN, Seay RE, Young LA, et al. Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. J Clin Anesth 1996; 8: 540–4
Unlugenc H, Guler T, Gunes Y, et al. Comparative study of the anti-emetic efficacy of ondansetron, propofol and midazolam in the early postoperative period. Eur J Anaesth 2004; 21: 60–5
Dick GS, Meller ST, Pinkerton CR. Randomized comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child 1995; 73: 243–5
Koseoglu V, Kürekçi AE, Sorici Ü, et al. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 1998; 157: 806–10
Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992; 19Suppl. 15: 26–32
Ang C, Habre W, Sims C. Tropisetron reduces vomiting after tonsillectomy in children. Br J Anaesth 1998; 80: 761–3
Cieslak GD, Watcha MF, Phillips MB, et al. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. Anesthesiology 1996; 85: 1076–85
Coopes MJ, Yanofsky R, Pritchard S, et al. Safety, tolerability, anti-emetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 1999; 21: 274–83
Fujii Y, Tanaka H, Ito M. Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in children. Br J Ophthalmol 2001; 85: 670–2
Holt R, Rask P, Coulthard KP, et al. Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy. Paediatr Anaesth 2000; 10: 181–8
Patel RI, Davis PJ, Orr RJ, et al. Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients. Anesth Analg 1997; 85: 538–45
Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc) 2002; 38: 75–89
De Negri P, Ivani G. Management of postoperative nausea and vomiting in children. Pediatr Drugs 2002; 4: 717–28
De Grandi T, Simon JE. Promethazine-induced dystonic reaction. Pediatr Emerg Care 1987; 3: 91–2
Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J 1999; 92: 1017–8
Marill KA, Walsh MJ, Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. Am Emerg Med 2000; 36: 310–9
McCall JE, Stubbs K, Saylors S, et al. The search for cost-effective prevention of postoperative nausea and vomiting in the child undergoing reconstructive burn surgery: ondansetron versus dimenhydrinate. J Burn Care Rehabil 1999; 20: 309–15
Schlager A, Mitterschiffthaler G, Pühringer F. Rectally administered dimenhydrinate reduces postoperative vomiting in children after strabismus surgery. Br J Anaesth 2000; 84: 405–6
Welters ID, Menges T, Gräf M, et al. Reduction of postoperative nausea and vomiting by dimenhydrinate suppositories for strabismus surgery in children. Anesth Analg 2000; 90: 311–4
Leung AK, Lai PC. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res 2004; 36: 911–5
Baines D. Postoperative nausea and vomiting in children. Paediatr Anaesth 1996; 6: 7–14
Berkovitch M, Mazzota P, Greenberg R, et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol 2002; 19: 311–6
Broadman LM, Ceruzzi W, Patane PS. Metoclopramide reduces the incidence of vomiting following strabismus surgery in children. Anesthesiology 1990; 72: 245–8
Lin DM, Furst SR, Rodarie A. A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery. Anesthesiology 1992; 76: 357–61
Fujii Y, Saitoh Y, Tanaka H, et al. Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis. Can J Anaesth 1998; 45: 153–6
Naguib M, El Bakry AK, Khoshim MHB, et al. Prophylactic anti-emetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth 1996; 43: 226–31
Rose JB, Martin TM, Corddry DH, et al. Ondansetron reduces the incidence and severity of post-strabismus repair vomiting in children. Anesth Analg 1994; 79: 486–9
Batts KF, Munter DW. Metoclopramide toxicity in an infant. Pediatr Emerg Care 1998; 14: 39–41
Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Arch Intern Med 1989; 149: 2486–92
Putnam PE, Orenstein SR, Wessel HB, et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992; 121: 983–5
Langford JS, Sheikh S. An adolescent case of sulfhemoglobinemia associated with high-dose metoclopramide and N-acetylcysteine. Ann Emerg Med 1993; 34: 538–41
Madani S, Tolia V. Gynecomastia with metoclopramide use in pediatric patients. J Clin Gastroenterol 1997; 24: 79–81
Wilson CM, Bird SG, Bocash W, et al. Methemoglobinemia following metoclopramide therapy in an infant. J Pediatr Gastroenterol Nutr 1987; 6: 640–2
Cooke RD, Comyn DJ, Ball RW. Prevention of postoperative nausea and vomiting by domperidone: a double-blind randomized study using domperidone, metoclopramide and a placebo. S Afr Med J 1979; 17: 827–9
Boghaert A, Carron D, Gallant J, et al. Postoperative vomiting treated with domperidone: a double-blind comparison with metoclopramide and a placebo. Acta Anesthesiol Belg 1980; 31: 129–37
Blanc UF, Ruest P, Milot J, et al. Anti-emetic prophylaxis with promethazine or droperidol in pediatric outpatient strabismus surgery. Can J Anaesth 1991; 38: 54–60
Fassoulaki A, Galanaki E. The anti-emetic effect of droperidol: is it dose dependent? Acta Anaesthesiol Belg 1989; 40: 179–82
Henzi I, Sondereggar J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anesth 2000; 47: 537–55
Verheecke G, Troch E. Oral droperidol for premedication in children. Acta Anaesthesiol Belg 1985; 4: 421–6
Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79: 983–6
Bardfeld PA. A controlled double-blind study of trimethobenzamide, prochlorperazine, and placebo. JAMA 1996; 196: 796–8
Ordog GJ, Vann PW, Owashi ND, et al. Intravenous prochlorperazine for the rapid control of vomiting in the emergency department. Ann Emerg Med 1984; 13: 253–8
Carey M, Aitken ME. Diverse effects of anti-emetic medication in children. NZ Med J 1994; 107: 452–3
Drotts DL, Vinson DR. Prochlorperazine induces akathisia in emergency patients. Ann Emerg Med 1999; 34: 469–75
Vinson DR, Drotts DZ. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 2001; 37: 125–31
Ginsburg CM, Clahsen J. Evaluation of trimethobenzamide hydrochloride (Tigan) suppositories for treatment of nausea and vomiting in children. J Pediatr 1980; 96: 767–9
Holmes C, Flaherty RJ. Trimethobenzamide hydrochloride (Tigan)-induced extra-pyramidal dysfunction in a neonate. J Pediatr 1976; 89: 669–70
Acknowledgements
No funding was used to assist in the preparation of this review. Dr Leung has received unrestricted educational grants from Merck Frosst Canada, Fujisawa Canada, Janssen-Ortho, Bristol-Myers Squibb Canada, and Sanofi Pasteur. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leung, A.K.C., Robson, W.L.M. Acute Gastroenteritis in Children. Pediatr-Drugs 9, 175–184 (2007). https://doi.org/10.2165/00148581-200709030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00148581-200709030-00006